U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07438626) titled 'Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma' on Feb. 23.
Brief Summary: To learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving at least 1 treatment.
Study Start Date: Aug. 17, 2026
Study Type: INTERVENTIONAL
Condition:
Phase II
Sacituzumab
Tirumotecan
SMARCB1-deficient Renal Medullary Carcinoma
Intervention:
DRUG: Sacituzumab tirumotecan
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services...